Vidal-Anzardo Margot, Solis Gilmer, Solari Lely, Minaya Gabriela, Ayala-Quintanilla Beatriz, Astete-Cornejo Jonh, Luque-Aguilar Amparo, Jorge Ana, Rojas Nancy, Cardenas Fanny, Soto Alonso
Centro Nacional de Salud Pública, Instituto Nacional de Salud, Lima, Perú.
Oficina General de Investigación y Transferencia Tecnológica, Instituto Nacional de Salud, Lima, Perú.
Rev Peru Med Exp Salud Publica. 2020 Apr-Jun;37(2):203-209. doi: 10.17843/rpmesp.2020.372.5534. Epub 2020 Aug 28.
To determine the additional diagnostic performance of a rapid serological test for detection of IgM and IgG antibodies compared to the real-time polymerase chain reaction (RT-PCR) test; for detection of SARS-CoV-2.
A cross-sectional study was carried out including patients hospitalized for COVID-19 in 3 hospitals, health workers exposed to the infection and outpatients who met suspicious case criteria, all of which underwent the molecular test (RT-PCR) and the rapid serological test. The additional diagnostic performance of rapid serological test was evaluated in comparison to molecular tests. Likewise, an approximation was made to the sensitivity and specificity of the rapid serological test.
144 people were included. With the rapid test, 19.4% of positive results were obtained compared to 11.1% in the molecular test (p = 0.03). The rapid serological test detected 21 cases that had been negative by the initial (RT-PCR), providing an additional diagnostic performance of 56.8% compared to the RT-PCR. The additional diagnostic performance was 50.0% during the first week, 70.0% during the second week and 50.0% during the third week of symptom onset. The sensitivity of the rapid serological test was 43.8% and the specificity of 98.9%.
The rapid serological test was able to detect a greater number of cases than those detected by the molecular test especially after the second week of onset of symptoms. It also showed high specificity. It is therefore useful as a complementary test to RT-PCR, especially during the second and third week of illness.
确定一种用于检测新型冠状病毒(SARS-CoV-2)的IgM和IgG抗体的快速血清学检测相对于实时聚合酶链反应(RT-PCR)检测的额外诊断性能。
开展了一项横断面研究,纳入了3家医院中因新冠肺炎住院的患者、接触过该感染的医护人员以及符合疑似病例标准的门诊患者,所有这些人都接受了分子检测(RT-PCR)和快速血清学检测。将快速血清学检测的额外诊断性能与分子检测进行比较评估。同样,对快速血清学检测的敏感性和特异性进行了估算。
共纳入144人。快速检测获得了19.4%的阳性结果,而分子检测为11.1%(p = 0.03)。快速血清学检测发现了21例最初(RT-PCR)检测为阴性的病例,相对于RT-PCR提供了56.8%的额外诊断性能。症状出现后的第一周额外诊断性能为50.0%,第二周为70.0%,第三周为50.0%。快速血清学检测的敏感性为43.8%,特异性为98.9%。
快速血清学检测能够检测出比分子检测更多的病例,尤其是在症状出现后的第二周之后。它还显示出高特异性。因此,它作为RT-PCR的补充检测很有用,尤其是在疾病的第二周和第三周。